BioScrip, Inc.s in-depth stock price analysis indicates that the stock price has rallied 23.13% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -37.74% . Looking at the past 52 week period, the stock price is up at 9.27% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of BioScrip, Inc. has a negative value of -51.4 compared to overall market performance. BioScrip, Inc. (NASDAQ:BIOS) has tumbled 7.82% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.23% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 8.56%. BioScrip, Inc. (NASDAQ:BIOS) has underperformed the index by 0.59% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
BioScrip, Inc. (NASDAQ:BIOS) : On Friday heightened volatility was witnessed in BioScrip, Inc. (NASDAQ:BIOS) which led to swings in the share price. The stock opened for trading at $1.65 and hit $1.69 on the upside , eventually ending the session at $1.65, with a gain of 1.85% or 0.03 points. The heightened volatility saw the trading volume jump to 1,482,286 shares. The 52-week high of the share price is $3.43 and the company has a market cap of $194 million. The 52-week low of the share price is at $0.98 .
BioScrip Inc Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.07. Analyst had a consensus of $-0.05. The company had revenue of $224.50 million for the quarter, compared to analysts expectations of $223.28 million. The companys revenue was down -9.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.38 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.BioScrip Inc was Initiated by Lake Street on Jan 3, 2017 to Buy, Price Target of the shares are set at $4.50.
Company has reported several Insider transactions to the SEC, on Nov 14, 2016, Jeffrey M Kreger (CFO) purchased 10,000 shares at 1.32 per share price.On Nov 14, 2016, Daniel E Greenleaf (CEO) purchased 16,000 shares at 1.30 per share price.On Nov 14, 2016, R Carter Pate (director) purchased 20,000 shares at 1.30 per share price.
BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: specialty medication distribution and clinical management services, both nationally and community-based and pharmacy benefit management services.